Miriam Retuerto

Dr. Miriam Retuerto

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
JPJose L Pablos
Jose L Pablos
MGMaría Galindo
María Galindo
LCLoreto Carmona
Loreto Carmona
ALAna Lledó
Ana Lledó
MRMiriam Retuerto
Miriam Retuerto
AFAntonio Fernandez-Nebro
Antonio Fernandez-Nebro
Objectives The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here, we compare the outcomes of a cohort of patients with rheumatic diseases with a matched control cohort to identify potential risk factors for severe illness. Methods In this comparative cohort study, we identified hospital PCR+COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or connective tissue diseases (CTDs). Non-rheumatic controls were randomly sampled 1:1 and matched by age, sex and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, intensive care unit admission or serious complications. We assessed the association between the outcome and the potential prognostic variables, adjusted by COVID-19 treatment, using logistic regression. Results The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 (IQR 53–78) years and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and CTD (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID-19 was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID-19 were increased age (OR 4.83; 95% CI 2.78 to 8.36), male sex (1.93; CI 1.21 to 3.07) and having a CTD (OR 1.82; CI 1.00 to 3.30). Conclusion In hospitalised patients with chronic inflammatory rheumatic diseases, having a CTD but not IA nor previous immunosuppressive therapies was associated with severe COVID-19.

12 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
JPJose L Pablos
Jose L Pablos
LALydia Abasolo
Lydia Abasolo
JAJose M Alvaro-Gracia
Jose M Alvaro-Gracia
FBFrancisco Blanco
Francisco Blanco
RBRicardo Blanco
Ricardo Blanco
ASAlvaro Seijas-Lopez
Alvaro Seijas-Lopez
Background The susceptibility of patients with rheumatic diseases and the risks or benefits of immunosuppressive therapies for COVID-19 are unknown. Methods We performed a retrospective study with patients under follow-up in rheumatology departments from seven hospitals in Spain. We matched updated databases of rheumatology patients with severe acute respiratory syndrome coronavirus 2-positive PCR tests performed in the hospital to the same reference populations. Rates of PCR+ confirmed COVID-19 were compared among groups. Results Patients with chronic inflammatory diseases had 1.32-fold higher prevalence of hospital PCR+ COVID-19 than the reference population (0.76% vs 0.58%). Patients with systemic autoimmune or immune-mediated disease (AI/IMID) showed a significant increase, whereas patients with inflammatory arthritis (IA) or systemic lupus erythematosus did not. COVID-19 cases in some but not all diagnostic groups had older ages than cases in the reference population. Patients with IA on targeted-synthetic or biological disease-modifying antirheumatic drugs (DMARDs), but not those on conventional-synthetic DMARDs, had a greater prevalence despite a similar age distribution. Conclusion Patients with AI/IMID show a variable risk of hospital-diagnosed COVID-19. Interplay of ageing, therapies and disease-specific factors seem to contribute. These data provide a basis to improve preventive recommendations to rheumatic patients and to analyse the specific factors involved in COVID-19 susceptibility.

27 March 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
MRMiriam Retuerto
Miriam Retuerto
RLRamiro López-Medrano
Ramiro López-Medrano
EFElizabeth María De Freitas-González
Elizabeth María De Freitas-González
OROctavio Miguel Rivero-Lezcano
Octavio Miguel Rivero-Lezcano
Nontuberculous mycobacteria (NTM) are environmental and ubiquitous, but only a few species are associated with disease, often presented as nodular/bronchiectatic or cavitary pulmonary forms. Bronchiectasis, airways dilatations characterized by chronic productive cough, is the main presentation of NTM pulmonary disease. The current Cole’s vicious circle model for bronchiectasis proposes that it progresses from a damaging insult, such as pneumonia, that affects the respiratory epithelium and compromises mucociliary clearance mechanisms, allowing microorganisms to colonize the airways. An important bronchiectasis risk factor is primary ciliary dyskinesia, but other ciliopathies, such as those associated with connective tissue diseases, also seem to facilitate bronchiectasis, as may occur in Lady Windermere syndrome, caused by M. avium infection. Inhaled NTM may become part of the lung microbiome. If the dose is too large, they may grow excessively as a biofilm and lead to disease. The incidence of NTM pulmonary disease has increased in the last two decades, which may have influenced the parallel increase in bronchiectasis incidence. We propose that ciliary dyskinesia is the main promoter of bronchiectasis, and that the bacteria most frequently involved are NTM. Restoration of ciliary function and impairment of mycobacterial biofilm formation may provide effective therapeutic alternatives to antibiotics.

16 December 2025 in Rheumatology
Verified
Journal Article
Open access
MRMiriam Retuerto
Miriam Retuerto
CMClara Moriano Morales
Clara Moriano Morales
APAna Pareja-Martínez
Ana Pareja-Martínez
NMNatalia Molina-Esteban
Natalia Molina-Esteban
JPJose Puig-Buendia
Jose Puig-Buendia
EÁElvira Díez Álvarez
Elvira Díez Álvarez
Objective: To assess real-world outcomes of anifrolumab (ANI) in refractory systemic DM. Methods: This multicentre and multidisciplinary, retrospective study evaluated 30 DM patients receiving ANI through compassionate use. Disease activity was assessed at baseline and months 1, 3, 6 and 12 using Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score (CDASI-A), Manual Muscle Testing-8 (MMT-8), joint and pulmonary evaluation and glucocorticoid tapering. Safety included adverse event documentation and treatment discontinuation rates. Results: Treatment indications included refractory cutaneous (73.3%), cutaneous-muscular (13.4%, including one pulmonary progression case) and other manifestations (13.3%). ANI was initiated without concomitant immunosuppressive therapy in 50% of patients. Cutaneous improvement was observed from month 1 (CDASI-A: 23 [IQR 10.8–30.5] to 6 [IQR 3–10]; P < 0.001), with heliotrope rash and Gottron’s papules responding faster than alopecia. Muscular function improved (MMT-8: 142.5 [IQR 127–148] to 146.5 [IQR 139–150]; P < 0.05) with creatine kinase (CK) normalization (332 IU/l [IQR 211.5–893.5] to 146 IU/l [IQR 106.5–481.8]) at month 1. All active arthritis patients (n = 3) achieved remission, with no articular flares observed among patients with historical joint involvement. Interstitial lung disease cases (n = 6) demonstrated stabilization or improvement as assessed by pulmonary function tests and/or computed tomography. Glucocorticoid dose significantly reduced (P < 0.001), discontinued in 50%. Adverse events were mild (16.7% patients); one 89-year-old patient died from pneumonia. One patient required upadacitinib for refractory pruritus; one discontinued ANI for efficacy loss. Conclusion: ANI showed rapid, multisystem efficacy in refractory DM with significant steroid-sparing effects and a favourable safety profile.

20 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
JPJosé L. Pablos
José L. Pablos
MGMaría Galindo-Izquierdo
María Galindo-Izquierdo
LCLoreto Carmona
Loreto Carmona
MRMiriam Retuerto
Miriam Retuerto
ALAna Lledó
Ana Lledó
AFAntonio Fernandez-Nebro
Antonio Fernandez-Nebro
Background: The impact of inflammatory rheumatic diseases on COVID-19 severity is poorly known. Here we compare the outcomes of a cohort of rheumatic patients with a matched control cohort to identify potential risk factors for severe illness. Methods: In this comparative cohort study, we identified hospital PCR+ COVID-19 rheumatic patients with chronic inflammatory arthritis (IA) or autoimmune/immunomediated diseases (AI/IMID). Non-rheumatic controls were randomly sampled 1:1, and matched by age, sex, and PCR date. The main outcome was severe COVID-19, defined as death, invasive ventilation, ICU admission, or serious complications. We assessed the association between the outcome and potential prognostic variables, adjusted by COVID treatment, using logistic regression. Results: The cohorts were composed of 456 rheumatic and non-rheumatic patients, in equal numbers. Mean age was 63 [IQR 53-78] and male sex 41% in both cohorts. Rheumatic diseases were IA (60%) and AI/IMID (40%). Most patients (74%) had been hospitalised, and the risk of severe COVID was 31.6% in the rheumatic and 28.1% in the non-rheumatic cohort. Ageing, male sex and previous comorbidity (obesity, diabetes, hypertension, cardiovascular, or lung disease) increased the risk in the rheumatic cohort by bivariate analysis. In logistic regression analysis, independent factors associated with severe COVID were increased age (OR 5.31; CI 3.14-8.95), male sex (2.13; CI 1.35-3.36) and having an AI/IMID (OR 1.98; CI 1.15-3.41). Conclusion: In patients with chronic inflammatory rheumatic diseases aging, sex and having an AI/IMID but not IA nor previous immunosuppressive therapies were associated with severe COVID-19.

1 January 2026 in RMD Open
Verified
Journal Article
Open access
PDF file
VCVanesa Calvo-Río
Vanesa Calvo-Río
CSCarmen Secada-Gómez
Carmen Secada-Gómez
AMAdrián Martín-Gutiérrez
Adrián Martín-Gutiérrez
MRMiriam Retuerto
Miriam Retuerto
JFJudit Font
Judit Font
RBRicardo Blanco
Ricardo Blanco
Background: Anifrolumab is approved for adults with moderate-to-severe active systemic lupus erythematosus (SLE) based on Randomised clinical trials (RCTs). While randomised pivotal RCTs have demonstrated their efficacy and safety, real-world evidence (RWE) remains limited. Objectives: To describe the clinical characteristics, effectiveness and safety of anifrolumab in clinical practice and to assess findings from published observational studies. Methods: Multicentre study of patients with SLE classified according to EULAR/American College of Rheumatology (ACR) 2019. Data were collected from medical records up to 30 April 2025. Variables included demographic characteristics, clinical and serological features, prior and concomitant therapies, disease activity indices including the SLE Disease Activity Index 2000 (SLEDAI-2K), SLE Disease Activity Score (SLE-DAS) and Physician Global Assessment (PGA), damage and disease control measures including the Systemic Lupus International Collaborating Clinics/ACR Damage Index, Lupus Low Disease Activity State (LLDAS) and Definitions of Remission in SLE (DORIS) remission and the association with adverse events (AEs). A review of published observational studies was also conducted. Results: We included 206 patients (183 women; mean age 44.6±12.6 years) from 54 Spanish centres. The most common indications for anifrolumab were cutaneous (61.7%), musculoskeletal (48.5%) and haematological (27.2%). A rapid and sustained improvement was observed in disease activity (SLEDAI-2K, SLE-DAS, PGA), LLDAS, DORIS remission, serological markers (anti-double-stranded DNA, C3/C4) and corticosteroid tapering. Organ damage remained stable. After a mean follow-up of 7.5±5.3 months, the most frequent AEs were herpes zoster (n= 5), respiratory infections (n= 6) and headache (n= 3). Twenty patients discontinued treatment. These results were consistent with published observational studies. Conclusion: In this large RWE cohort, anifrolumab demonstrated early and sustained clinical benefit, a favourable safety profile and a significant corticosteroid-sparing effect. These findings reinforce the evidence from CT and support the incorporation of anifrolumab into routine care for patients with SLE.